Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.